Life Science Nation Newsletter | March 14, 2019 | Issue 308


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
   Life Science Investor Mandates
(Mar. 7 - Mar. 13 )
Seeks to Lead Investments in Cardiovascular, Ophthalmology, and Regenerative Medicine Companies
Seeks to Partner with Novel Diagnostics Companies that Target Oncology, Metabolic Disease, Infectious Disease, etc.
Invests Up to $25M in Disruptive Medical Device Technologies, with More Selective Interest in Diagnostics and Digital Health
Invests Across Therapeutics, Medical Devices, and Diagnostics Companies in All Indications
News
LSN Services
LSN Videos
LSN Media Partners
By Karen Deyo, Investor Research Analyst, LSN

The inaugural RESI Europe is just around the corner, and with that, we are happy to announce the finalists for the RESI Innovation Challenge. On March 25th in Vienna, these finalists will present posters of their technologies in the Exhibition Hall. From therapeutics to devices, diagnostics to digital health, the technologies are as diverse as the countries these companies represent, with startups participating from all over Europe, Israel and even from the US. We encourage all attendees to take the opportunity to check out all of these companies and their technologies and to "invest" your "RESI cash" in your favorite(s). The top three companies will receive prizes at the end of the day, so make sure to go through the exhibition hall and cast your votes!

Thank you to all of the companies that submitted applications to the Innovation Challenge - we encourage you to try again at a future RESI. Good luck to the finalists, and we look forward to seeing you in Vienna...

Therapeutic

 

Diagnostic

 

MedTech Device

 

Digital Health

By Claire Jeong, Director of Research, Asia BD, LSN

While the life sciences industry is constantly subject to dynamic changes and trends, oncology/Immuno-oncology continues to be one of the most popular areas to invest in. Though some firms shy away from the indication due to it being an overcrowded space, there are many firms who strongly - or even solely focus - on oncology. From relatively traditional modalities such as small molecules (such as the $1B Celgene partnership with Triphase Accelerator/FACIT that happened earlier this year) to rapidly emerging approaches like oncolytic viruses and cell/gene therapy, there are still many promising therapies and novel approaches that have not yet come to light.

The Oncology Innovation panel at the upcoming RESI Europe Conference in Vienna, will highlight 5 speakers who actively seek investment opportunities in oncology. The panel will run from 1:00 - 1:50 pm on the day of RESI Europe, Monday, March 25 th, 2019, so if you are a company attending RESI who is working on innovative oncology therapies, you would not want to miss out on this panel. Here is our lineup of panelists:
  • Claus Andersson, General Partner, Sunstone Life Science Ventures (Moderator)
  • Toshiyasu Shimomura, Senior Investment Director, Taiho Ventures
  • Hakan Goker, Senior Investment Director, M Ventures
  • Mark Krul, Partner, Aglaia Oncology Funds
  • Katherine Cohen, Venture Partner, Panacea Venture
By Lucy Parkinson, VP of Investor Research, LSN

There's a widespread perception that funding and launching new diagnostic technologies is a difficult undertaking. In addition to the scientific and technical challenges of developing a new product, diagnostic entrepreneurs need to build a solid business case that will indicate future success. Many fail to realize that investors will be as interested in evidence of market traction and physician support than in signals of diagnostic sensitivity and specificity.

At RESI Europe, five experienced senior staff from investment firms and major strategics in the industry will explain how they look for good bets in the diagnostics field. Representing a spectrum from early stage investment to potential exit partner, these investors will explain to the audience what it takes to get a diagnostic funded and how they help startups bring new tests and monitoring solutions to market.

Moderator Tom Miller, Managing Partner, Greybird Ventures will put questions to the panelists:
  • Walter Stockinger, Managing Partner, Hadean Ventures
  • Michael Sidler, General Partner, Redalpine
  • Ekkehard Kauffmann, Global Business Development M&A, Roche Diagnostics

Created & Produced by